Description
Osimertinib mesylate is approved to treat:
- Non-small cell lung cancer that has certain EGFR gene mutations. It is used in adults:
Osimertinib mesylate is also being studied in the treatment of other types of cancer.
The active substance in Tagrisso, osimertinib, is a type of cancer medicine called a tyrosine kinase inhibitor. It blocks the activity of EGFR, which normally controls growth and division of cells. In lung cancer cells, EGFR is often overactive, causing uncontrolled growth of cancer cells. By blocking EGFR, osimertinib helps to reduce the growth and spread of the cancer.